This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The primary efficacy and safety outcomes were stroke or systemic embolic events (stroke/SEE) and major bleeding, respectively; secondary outcomes were ischemic stroke/SEE, intracranial hemorrhage, death, and the net clinical outcome (stroke/SEE, major bleeding, or death). Each outcome was examined across BMI and BW.
In addition, abelacimab consistently reduced bleeding risk in patients 75 years of age and older regardless of renal function, body mass index (BMI), and the use of concomitant antiplatelet therapy. Patients with atrialfibrillation, particularly older patients, are frequently at a high risk of bleeding.
Background Catheter ablation (CA) for symptomatic atrialfibrillation (AF) offers the best outcomes for patients. The probability of freedom from atrial arrhythmia with repeat procedures is as follows: year 1: 0.95, year 2: 0.92, year 3: 0.85, year 4: 0.79, and year 5: 0.72. Age >75 years ( p = 0.02, HR: 2.7,
It incorporates age, body mass index (BMI), and atrialfibrillation to aid in the diagnosis of HFpEF. The newly developed HFpEF-ABA score model estimates the probability of HFpEF in individual patients based on three simple clinical variables: age, BMI, and atrialfibrillation.
ABSTRACT Introduction Catheter ablation of persistent atrialfibrillation yields sub-optimal success rates partly due to the considerable heterogeneity within the patient population. Methods We studied all patients who underwent catheter ablation of persistent atrialfibrillation in the DECAAF II trial.
Limited data indicate an elevated risk of atrialfibrillation (AF) after neoadjuvant chemoradiation in esophageal cancer however the role of AF as an independent predictor of outcomes post-esophagectomy remains under-studied. Outcomes over a 5-year period were mortality, ischemic stroke, and use of anticoagulation.
Previous studies have shown that a higher BMI is associated with AF recurrence after AF ablation using conventional thermal ablative modalities, such as radiofrequency (RF) or cryotherapy (Cryo).
BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association. Abstract Aims Mineralocorticoid receptor antagonists (MRA) improve outcomes in heart failure with reduced ejection fraction (HFrEF) but are underused. 1.38), a diagnosis of atrialfibrillation (HR 1.24, 95% CI 1.10–1.39),
Abstract Introduction Obesity is implicated in adverse atrial remodeling and worse outcomes in patients with atrialfibrillation. The objective of this study is to assess the effect of body mass index (BMI) on ablation-induced scar formation on late gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMR).
The primary outcome was to estimate the prevalence of cardiovascular risk factors in patients with hemophilia compared to the general population. Further research is to identify potential ex-specific risk factors that predispose to worse cardiovascular outcomes among patients with hemophilia.
Propensity score-matched analysis (PSM) (1:1) was performed with matching for age, gender, race, BMI, hypertension, diabetes mellitus, chronic kidney disease, hemoglobin level, low-density lipid (LDL) level, left ventricular ejection fraction, and various drugs including ACEi, ARBi, ARNI, beta-blockers, and diuretics. years, with 49.27% men.
Then identified clusters are predicted and tested in the learning set to evaluate their association with outcomes. Clusters were significantly associated with outcomes in derivation and validation datasets, with Cluster 1 having the highest risk, and Cluster 4 the lowest.
The primary outcome was incident ischemic stroke. Participants with LVI were significantly older, male, Black, had higher BMI, and lower HDL. Participants with LVI were more likely to have diabetes, tobacco use, and atrialfibrillation (24% versus 14%, p<0.001). with LVI, n=2,282 or 88.3% without LVI).
Share Cardiovascular Disease Those in the ‘Ideal’ category were 55% less likely to develop diseases of the circulatory system, including: Heart Disease Stroke Heart Failure AtrialFibrillation For each 10-point increment in lifestyle score, there was a proportionate 20% reduction in these conditions combined.
Objective While greater body mass index (BMI) is associated with increased risk of developing atrialfibrillation (AF), the impact of BMI on outcomes in newly diagnosed AF is unclear. The study population comprised 40 482 participants: 703 underweight (BMI <18.5 kg/m 2 ), 13 095 normal (BMI=18.5–24.9
Introduction:Atrial fibrillation (AF) is a common cardiac arrhythmia, the risk of cardiovascular adverse outcome rises when it coexists with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI).
mg administered to participants once weekly vs placebo on the STEP-HFpEF program’s dual primary and confirmatory secondary, and exploratory outcomes by sex. Semaglutide-mediated improvements in HF-related symptoms and physical limitations were consistent in both male and female participants across key subgroups including age and BMI.
We sought to identify the differential clinical and neuroimaging characteristics, and outcomes in matched AIS cohorts from Norway (NOR) and the United States (US).Methods:AIS Cohorts were matched on age, sex, diabetes, atrialfibrillation, and hypertension. Likewise, WMH burden was similar across cohorts.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
80 
Let's personalize your content